Phase 2 N=97 Low-dose Atropine for the Prevention of Myopia Progression in Danish Children
Myopia
Primary: Axial Length at 36 Months — 25.28; 25.25; 25.33 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Effectiveness of Orthokeratology in Myopia Control
Myopia
Primary: Axial Length — 25.32; 26.08 mm
Phase 3 N=122 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Myopia, Pathological
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…
Phase 3 N=200 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Choroidal Neovascularization Secondary to Pathologic Myopia
Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001
Phase 3 N=277 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Pathological Myopia
Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters
Phase 3 N=457 Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001
Phase 3 N=118 Correction of Myopia Evaluation Trial 2
Myopia
Primary: Distribution of Change in Spherical Equivalent Refractive Error From Baseline to 3 Years — 6; 3; 11; 8 participants
N/A N=100 Myopia Assessment of Two Manufacturing Processes
Juvenile Myopia
Primary: Change in Axial Length Progression From Baseline — 0.046; 0.047 mm
Phase 3 N=187 Low-Dose Atropine for Treatment of Myopia
Myopia
Primary: Treatment Group Comparison of Change in Spherical Equivalent Refractive Error. — 0; 0; 1; 0 Participants
N/A N=71 Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate
Myopia
Primary: Annualized Changes in Refractive Error (SER) — -0.70; -0.66 Dioptre/year
N/A N=127 Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control)
Myopia
Primary: Spherical Equivalent Refractive Error — -0.386; -0.185; -0.679; -0.548 diopter (D)
N/A N=152 Controlling Myopia Progression With Soft Contact Lenses
Myopia
Primary: Axial Length (Axial Elongation) — 0.158; 0.144; 0.121; 0.242 millimeter (mm)
N/A N=137 Controlling Myopia Progression With Soft Contact Lenses
Myopia
Primary: Spherical Equivalent Refraction — -0.326; -0.460; -0.430; -0.898 diopter (D)
N/A N=92 Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes
Myopia
Primary: Axial Lenght Increase — 0.27; 0.37 mm
N/A N=114 VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia
Myopia · Refractive Errors
Primary: Variability of the Refractive Predicatibility — -0.22 Diopters
N/A N=86 Bifocal Soft Contact Lenses and Their Effect on Myopia Progression in Children and Adolescents.
Myopia · Esophoria · Fixation Disparity
Primary: Changes in Cycloplegic Autorefraction in One Year. — -0.22; -0.78 Diopters
N/A N=102 Retardation of Myopia in Orthokeratology
Myopia
Primary: Axial Elongation in the Study and Control Subjects Who Completed the Two Years Study — 0.36; 0.63 mm
N/A N=183 Myopia Control With the Multi-segment Lens
Myopia
Primary: Cycloplegic Refraction Change in SER — -0.93; -0.38 Diopters (D)
N/A N=49 Bifocal & Atropine in Myopia (BAM) Study
Refractive Errors
Primary: Refractive Error Progression — -3.50 Diopter — p=0.70
N/A N=100 Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality
Myopia-Night Blindness
Primary: Night Myopia — -0.30; -0.32 D
N/A N=144 An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression
Myopia
Primary: Change in Refractive Error Relative to Baseline — -0.18; -0.58 Diopters
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
N/A N=248 Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control
Myopia
Primary: The Statistical Correlation Between Three-year Change in Choroidal Thickness and Three-year Change in Axial Length — 0.18 mm axial length — p=<0.001
N/A N=82 Myopia Progression After Ceasing Myopia Control Contact Lens Wear
Myopia
Primary: Axial Length of the Eye — 0.080; 0.073; 0.229; 0.231 millimeter (mm)
N/A N=36 Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters
Myopic Progression
Primary: Changes in Spherical Equivalent Refraction — 2.31; 2.52 D
N/A N=59 Corneal Biomechanics and Corneal Reshaping Therapy
Myopia
Primary: Change of Corneal Stiffness From Baseline at 6 Months — 0.061 N/mm
Phase 2 N=42 Dilated Versus Non-Dilated Wavefront Corrections for Patients With Down Syndrome
Down Syndrome · Refractive Errors
Primary: Distance Visual Acuity — 0.41; 0.41; 0.40; 0.43 logMAR — p=0.92
N/A N=53 Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children
Myopia
Primary: Change in Axial Length — 0.153; 0.087; 0.082; 0.059 mm
N/A N=35 Enhancement of Emmetropization in Highly Hyperopic Infants
Hyperopia
Primary: Central Cycloplegic Refractive Error With Retinoscopy — 1.6; 1.2; 2.8 Diopters
N/A N=9 Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
Low Vision · Age Related Macular Degeneration
Primary: Tilt of the PCIOL and IOPCL MAG Complex — 9; 9 Eyes